Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for 10 companies, including Mingyu Pharmaceutical, which is required to clarify the compliance of its equity structure and reverse mergers [1] - Mingyu Pharmaceutical has submitted its application to the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as joint sponsors [1] - The CSRC requests legal opinions on various compliance issues related to equity structure, foreign exchange management, and investment regulations [1][2] Group 2 - Mingyu Pharmaceutical was established in 2018 and is a biotechnology innovation company with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody (bsAb) [3] - The company is advancing its own immune assets that are in late clinical stages towards commercialization [3]
明宇制药拟港股上市 中国证监会要求补充说明股权架构搭建及返程并购的合规性等
Zhi Tong Cai Jing·2026-01-09 12:57